{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:52:37Z","timestamp":1789080757069,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gilead Sciences Europe Ltd"},{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The global prevalence of invasive fungal infections (IFI) is increasing, particularly within Intensive Care Units (ICU), where\n                      <jats:italic>Candida<\/jats:italic>\n                      spp. and\n                      <jats:italic>Aspergillus<\/jats:italic>\n                      spp. represent the most important pathogens. Diagnosis and management of IFIs becomes progressively challenging, with increasing antifungal resistance and the emergence of rare fungal species.\n                    <\/jats:p>\n                    <jats:p>Through a consensus survey focused on assessing current views on how IFI should be managed, the aim of this project was to identify challenges around diagnosing and managing IFIs in the ICU. The current status in different countries and perceived challenges to date amongst a multidisciplinary cohort of healthcare professionals involved in the care of IFI in the ICU was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a modified Delphi approach, an expert panel developed 44 Likert-scale statements across 6 key domains concerning patient screening and minimal standards for diagnosis of IFIs in ICU; initiation and termination of antifungal treatments and how to minimise their side effects and insights for future research on this topic. These were used to develop an online survey which was distributed on a convenience sampling basis utilising the subscriber list held by an independent provider (M3 Global). This survey was distributed to intensivists, infectious disease specialists, microbiologists and antimicrobial\/ICU pharmacists within the UK, Germany, Spain, France and Italy. The threshold for consensus was set at 75%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 335 responses were received during the five-month collection period. From these, 29\/44 (66%) statements attained very high agreement (90%), 11\/44 (25%) high agreement (&lt;\u200990% and\u2009\u2265\u200975%), and 4\/44 (9%) did not meet threshold for consensus (&lt;\u200975%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results outline the need for physicians to be aware of the local incidence of IFI and the associated rate of azole resistance in their ICUs. Where high clinical suspicion exists, treatment should start immediately and prior to receiving the results from any diagnostic test. Beta-D-glucan testing should be available to all ICU centres, with results available within 48\u00a0h to inform the cessation of empirical antifungal therapy. These consensus statements and proposed measures may guide future areas for further research to optimise the management of IFIs in the ICU.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11046-024-00852-3","type":"journal-article","created":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T08:01:32Z","timestamp":1714896092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit"],"prefix":"10.1007","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-2824","authenticated-orcid":false,"given":"Martin","family":"Hoenigl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Enoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Wyncoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cortegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,5]]},"reference":[{"issue":"1","key":"852_CR1","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S2666-5247(22)00261-0","volume":"4","author":"J Salmanton-Garc\u00eda","year":"2023","unstructured":"Salmanton-Garc\u00eda J, Hoenigl M, Gangneux JP, Segal E, Alastruey-Izquierdo A, Arikan Akdagli S, et al. The current state of laboratory mycology and access to antifungal treatment in europe: a european confederation of medical mycology survey. Lancet Microbe. 2023;4(1):e47-56. https:\/\/doi.org\/10.1016\/S2666-5247(22)00261-0. (Epub 2022 Dec 1 PMID: 36463916).","journal-title":"Lancet Microbe"},{"issue":"9","key":"852_CR2","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3390\/jof8090946","volume":"8","author":"J Poissy","year":"2022","unstructured":"Poissy J, Rouz\u00e9 A, Cornu M, Nseir S, Sendid B. The changing landscape of invasive fungal infections in ICUs: a need for risk stratification to better target antifungal drugs and the threat of resistance. J Fungi (Basel). 2022;8(9):946. https:\/\/doi.org\/10.3390\/jof8090946.","journal-title":"J Fungi (Basel)"},{"issue":"10","key":"852_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","volume":"25","author":"P Koehler","year":"2019","unstructured":"Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild MJGT, Bohlius J, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25(10):1200\u201312. https:\/\/doi.org\/10.1016\/j.cmi.2019.04.024. (Epub 2019 Apr 27 PMID: 31039444).","journal-title":"Clin Microbiol Infect"},{"key":"852_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/jac\/dkz038","volume":"74","author":"M Cuenca-Estrella","year":"2019","unstructured":"Cuenca-Estrella M, Kett DH, Wauters J. Defining standards of CARE for invasive fungal diseases in the ICU. J Antimicrob Chemother. 2019;74:9\u201315. https:\/\/doi.org\/10.1093\/jac\/dkz038.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"852_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eimc.2019.10.002","volume":"38","author":"I Ruiz Camps","year":"2020","unstructured":"Ruiz Camps I. Aspergillosis: beyond the oncohematological patient. Enferm Infecc Microbiol Clin Engl Ed. 2020;38(1):1\u20133.","journal-title":"Enferm Infecc Microbiol Clin Engl Ed"},{"issue":"3","key":"852_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1439-0507.2009.01691.x","volume":"52","author":"C Lass-Fl\u00f6rl","year":"2009","unstructured":"Lass-Fl\u00f6rl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52(3):197\u2013205. https:\/\/doi.org\/10.1111\/j.1439-0507.2009.01691.x. (PMID: 19391253).","journal-title":"Mycoses"},{"issue":"2","key":"852_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","volume":"49","author":"A Tabah","year":"2023","unstructured":"Tabah A, Buetti N, Staiquly Q, Ruckly S, Akova M, Aslan AT, et al. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study. Intensive Care Med. 2023;49(2):178\u201390.","journal-title":"Intensive Care Med"},{"issue":"6","key":"852_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1473-3099(20)30847-1","volume":"21","author":"P Koehler","year":"2021","unstructured":"Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21(6):149\u201362. https:\/\/doi.org\/10.1016\/S1473-3099(20)30847-1.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"852_CR9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"AFAD Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782\u201392. https:\/\/doi.org\/10.1016\/S2213-2600(18)30274-1. (Epub 2018 Jul 31 PMID: 30076119).","journal-title":"Lancet Respir Med"},{"issue":"7","key":"852_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/j.1469-0691.2009.03015.x","volume":"16","author":"J Guinea","year":"2010","unstructured":"Guinea J, Torres-Narbona M, Gij\u00f3n P, Mu\u00f1oz P, Pozo F, Pel\u00e1ez T, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect. 2010;16(7):870\u20137. https:\/\/doi.org\/10.1111\/j.1469-0691.2009.03015.x. (Epub 2009 Nov 10 PMID: 19906275).","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"852_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s41564-022-01172-2","volume":"7","author":"M Hoenigl","year":"2022","unstructured":"Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127\u201340. https:\/\/doi.org\/10.1038\/s41564-022-01172-2.","journal-title":"Nat Microbiol"},{"issue":"4","key":"852_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/jof8040415.PMID:35448646;PMCID:PMC9025868","volume":"8","author":"F Raffaelli","year":"2022","unstructured":"Raffaelli F, Tanzarella ES, De Pascale G, Tumbarello M. Invasive respiratory fungal infections in COVID-19 critically ill patients. J Fungi (Basel). 2022;8(4):415. https:\/\/doi.org\/10.3390\/jof8040415.PMID:35448646;PMCID:PMC9025868.","journal-title":"J Fungi (Basel)"},{"issue":"11","key":"852_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/jof7110921.PMID:34829210;PMCID:PMC8620819","volume":"7","author":"G Casalini","year":"2021","unstructured":"Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive fungal infections complicating COVID-19: a narrative review. J Fungi (Basel). 2021;7(11):921. https:\/\/doi.org\/10.3390\/jof7110921.PMID:34829210;PMCID:PMC8620819.","journal-title":"J Fungi (Basel)"},{"issue":"3","key":"852_CR14","doi-asserted-by":"publisher","first-page":"e0137322","DOI":"10.1128\/spectrum.01373-22","volume":"10","author":"M Egger","year":"2022","unstructured":"Egger M, Pr\u00fcller F, Krause R, Prattes J, Hoenigl M. (2022) Utility of serum 1,3-\u03b2-d-glucan testing for diagnosis and prognostication in COVID-19-associated pulmonary aspergillosis. Microbiol Spectr. 2022;10(3):e0137322. https:\/\/doi.org\/10.1128\/spectrum.01373-22.","journal-title":"Microbiol Spectr."},{"issue":"8","key":"852_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/myc.12927","volume":"62","author":"EE Tejerina","year":"2019","unstructured":"Tejerina EE, Abril E, Padilla R, Rodr\u00edguez Ru\u00edz C, Ballen A, Frutos-Vivar F, et al. Invasive aspergillosis in critically ill patients: an autopsy study. Mycoses. 2019;62(8):673\u20139. https:\/\/doi.org\/10.1111\/myc.12927. (Epub 2019 Jun 9 PMID: 31177621).","journal-title":"Mycoses"},{"key":"852_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4939-6515-1_2","volume":"1508","author":"DA Enoch","year":"2017","unstructured":"Enoch DA, Yang H, Aliyu SH, Micallef C. The changing epidemiology of invasive fungal infections. Methods Mol Biol. 2017;1508:17\u201365. https:\/\/doi.org\/10.1007\/978-1-4939-6515-1_2. (PMID: 27837497).","journal-title":"Methods Mol Biol"},{"issue":"1","key":"852_CR17","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3390\/molecules19011085","volume":"19","author":"E Paramythiotou","year":"2014","unstructured":"Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G. Invasive fungal infections in the ICU: how to approach, how to treat. Molecules. 2014;19(1):1085\u2013119. https:\/\/doi.org\/10.3390\/molecules19011085.","journal-title":"Molecules"},{"key":"852_CR18","doi-asserted-by":"publisher","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","volume":"4","author":"PG Pappas","year":"2018","unstructured":"Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis Nat Rev Dis Primers. 2018;4:18026. https:\/\/doi.org\/10.1038\/nrdp.2018.26. (PMID: 29749387).","journal-title":"Invasive candidiasis Nat Rev Dis Primers"},{"key":"852_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00872-6","author":"M Hoenigl","year":"2023","unstructured":"Hoenigl M, Salmanton-Garc\u00eda J, Egger M, Gangneux JP, Bicanic T, Arikan-Akdagli S, et al. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. Lancet Infect Dis. 2023. https:\/\/doi.org\/10.1016\/S1473-3099(22)00872-6.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"852_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s11046-023-00776-4","volume":"188","author":"M Egger","year":"2023","unstructured":"Egger M, Salmanton-Garc\u00eda J, Barac A, Gangneux JP, Guegan H, Arsic-Arsenijevic V, et al. Predictors for prolonged hospital stay solely to complete intravenous antifungal treatment in patients with candidemia: results from the ECMM Candida III multinational european observational cohort study. Mycopathologia. 2023;188(6):983\u201394.","journal-title":"Mycopathologia"},{"key":"852_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(24)00039-9","author":"D Seidel","year":"2024","unstructured":"Seidel D, Wurster S, Jenks JD, Sati H, Gangneux JP, Egger M, Alastruey-Izquierdo A, Ford NP, Chowdhary A, Sprute R, Cornely O, Thompson GR 3rd, Hoenigl M, Kontoyiannis DP. Impact of climate change and natural disasters on fungal infections. Lancet Microbe. 2024. https:\/\/doi.org\/10.1016\/s2666-5247(24)00039-9.","journal-title":"Lancet Microbe"},{"issue":"Suppl 2","key":"852_CR22","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1093\/cid\/ciaa1751","volume":"72","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Azoulay E, Kullberg BJ, Ruhnke M, Shoham S, Vazquez J, et al. EORTC\/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group. Clin Infect Dis. 2021;72(Suppl 2):S121\u20137. https:\/\/doi.org\/10.1093\/cid\/ciaa1751. (PMID: 33709127).","journal-title":"Clin Infect Dis"},{"issue":"6","key":"852_CR23","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/cid\/ciq206","volume":"52","author":"DE Karageorgopoulos","year":"2011","unstructured":"Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. \u03b2-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52(6):750\u201370. https:\/\/doi.org\/10.1093\/cid\/ciq206. (PMID: 21367728).","journal-title":"Clin Infect Dis"},{"key":"852_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2257597","author":"R Aerts","year":"2023","unstructured":"Aerts R, Autier B, Gornicec M, Prattes J, Lagrou K, Gangneux JP, et al. Point-of-care testing for viral-associated pulmonary aspergillosis. Expert Rev Mol Diagn. 2023. https:\/\/doi.org\/10.1080\/14737159.2023.2257597.","journal-title":"Expert Rev Mol Diagn"},{"issue":"Suppl 2","key":"852_CR25","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1093\/cid\/ciaa1786","volume":"72","author":"T Mercier","year":"2021","unstructured":"Mercier T, Castagnola E, Marr KA, Wheat LJ, Verweij PE, Maertens JA. Defining galactomannan positivity in the updated EORTC\/MSGERC consensus definitions of invasive fungal diseases. Clin Infect Dis. 2021;72(Suppl 2):S89\u201394. https:\/\/doi.org\/10.1093\/cid\/ciaa1786. (PMID: 33709125).","journal-title":"Clin Infect Dis"},{"issue":"8","key":"852_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1473-3099(20)30784-2","volume":"21","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, Salmanton-Garc\u00eda J, Walsh TJ, Nucci M, Neoh CF, Jenks JD, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the european confederation of medical mycology in cooperation with the international society for human and animal mycology and the american society for microbiology. Lancet Infect Dis. 2021;21(8):246\u201357. https:\/\/doi.org\/10.1016\/S1473-3099(20)30784-2.","journal-title":"Lancet Infect Dis"},{"key":"852_CR27","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.6.3.e34","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G. Improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES). J Med Internet Res. 2004. https:\/\/doi.org\/10.2196\/jmir.6.3.e34.","journal-title":"J Med Internet Res"},{"issue":"1","key":"852_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","volume":"23","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23(1):219. https:\/\/doi.org\/10.1186\/s13054-019-2497-3.","journal-title":"Crit Care"},{"issue":"4","key":"852_CR29","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cmi.2021.08.014","volume":"28","author":"J Prattes","year":"2022","unstructured":"Prattes J, Wauters J, Giacobbe DR, Salmanton-Garc\u00eda J, Maertens J, Bourgeois M, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European confederation of medical mycology. Clin Microbiol Infect. 2022;28(4):580\u20137. https:\/\/doi.org\/10.1016\/j.cmi.2021.08.014.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"852_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40121-021-00585-6","volume":"11","author":"M Bassetti","year":"2022","unstructured":"Bassetti M, Vena A, Giacobbe DR, Trucchi C, Ansaldi F, Antonelli M, et al. Risk factors for intra-abdominal candidiasis in intensive care units: results from EUCANDICU study. Infect Dis Ther. 2022;11(2):827\u201340. https:\/\/doi.org\/10.1007\/s40121-021-00585-6.","journal-title":"Infect Dis Ther"},{"issue":"12","key":"852_CR31","doi-asserted-by":"publisher","first-page":"e0122921","DOI":"10.1128\/JCM.01229-21","volume":"59","author":"M Erg\u00fcn","year":"2021","unstructured":"Erg\u00fcn M, Br\u00fcggemann RJM, Alanio A, Delli\u00e8re S, van Arkel A, Bentvelsen RG, et al. aspergillus test profiles and mortality in critically ill COVID-19 patients. J Clin Microbiol. 2021;59(12):e0122921. https:\/\/doi.org\/10.1128\/JCM.01229-21.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"852_CR32","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","volume":"49","author":"M Morrell","year":"2005","unstructured":"Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640\u20135. https:\/\/doi.org\/10.1128\/AAC.49.9.3640-3645.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"852_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1086\/504810","volume":"43","author":"KW Garey","year":"2006","unstructured":"Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43(1):25\u201331. https:\/\/doi.org\/10.1086\/504810. (Epub 2006 May 16 PMID: 16758414).","journal-title":"Clin Infect Dis"},{"issue":"11","key":"852_CR34","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1099\/jmm.0.000612","volume":"66","author":"C Micallef","year":"2017","unstructured":"Micallef C, Ashiru-Oredope D, Hansraj S, Denning DW, Agrawal SG, Manuel RJ, et al. An investigation of antifungal stewardship programmes in England. J Med Microbiol. 2017;66(11):1581\u20139. https:\/\/doi.org\/10.1099\/jmm.0.000612. (Epub 2017 Oct 25 PMID: 29068278).","journal-title":"J Med Microbiol"},{"issue":"2","key":"852_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jinf.2019.06.009","volume":"79","author":"S Schelenz","year":"2019","unstructured":"Schelenz S, Owens K, Guy R, Rautemaa-Richardson R, Manuel RJ, Richardson M, et al. National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: Evidence of sub-optimal practice. J Infect. 2019;79(2):167\u201373. https:\/\/doi.org\/10.1016\/j.jinf.2019.06.009. (Epub 2019 Jun 21 PMID: 31233810).","journal-title":"J Infect"},{"key":"852_CR36","unstructured":"ECMM. European confederation of medical mycology one world\u2013one guideline. Available from: https:\/\/www.ecmm.info\/guidelines\/ Accessed 20 February 2023"},{"issue":"4","key":"852_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/myc.12869","volume":"62","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Scudeller L, Giacobbe DR, Lamoth F, Righi E, Zuccaro V, et al. Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units protocol of the FUNgal infections definitions in ICU patients (FUNDICU) project. Mycoses. 2019;62(4):310\u20139.","journal-title":"Mycoses"},{"issue":"4","key":"852_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/590004","volume":"47","author":"G Chamilos","year":"2008","unstructured":"Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503\u20139. https:\/\/doi.org\/10.1086\/590004. (PMID: 18611163).","journal-title":"Clin Infect Dis"},{"key":"852_CR39","unstructured":"Lewis T. and Dymond S. Diagnosis and management of fungal infections in critical care guideline. 2020. https:\/\/www.northdevonhealth.nhs.uk\/wp-content\/uploads\/2020\/08\/Antifungal-Guidelines-for-Critical-Care-Patients-v1.0-28012020.pdf Accessed 14 February 2023."},{"issue":"3","key":"852_CR40","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1055\/s-0042-1742632","volume":"14","author":"TK Sandhar","year":"2022","unstructured":"Sandhar TK, Chhina DK, Gupta V, Chaudhary J. Role of (1\u20133)-\u0392-D-glucan test in the diagnosis of invasive fungal infections among high-risk patients in a tertiary care hospital. J Lab Physicians. 2022;14(3):306\u201311. https:\/\/doi.org\/10.1055\/s-0042-1742632.","journal-title":"J Lab Physicians"},{"issue":"4","key":"852_CR41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/cid\/cis456","volume":"55","author":"S Jaijakul","year":"2012","unstructured":"Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-\u03b2-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55(4):521\u20136. https:\/\/doi.org\/10.1093\/cid\/cis456. (Epub 2012 May 9 PMID: 22573851).","journal-title":"Clin Infect Dis"},{"issue":"12","key":"852_CR42","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1093\/jac\/dky360","volume":"73","author":"R Rautemaa-Richardson","year":"2018","unstructured":"Rautemaa-Richardson R, Rautemaa V, Al-Wathiqi F, Moore CB, Craig L, Felton TW, Muldoon EG. Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital. J Antimicrob Chemother. 2018;73(12):3488\u201395. https:\/\/doi.org\/10.1093\/jac\/dky360. (PMID: 30252053).","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"852_CR43","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13054-017-1763-5","volume":"21","author":"DR Giacobbe","year":"2017","unstructured":"Giacobbe DR, Mikulska M, Tumbarello M, Furfaro E, Spadaro M, Losito AR, et al. Combined use of serum (1,3)-\u03b2-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. Crit Care. 2017;21(1):176. https:\/\/doi.org\/10.1186\/s13054-017-1763-5.","journal-title":"Crit Care"},{"issue":"1","key":"852_CR44","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13054-019-2481-y","volume":"23","author":"A Cortegiani","year":"2019","unstructured":"Cortegiani A, Misseri G, Ippolito M, Bassetti M, Giarratano A, Martin-Loeches I, et al. Procalcitonin levels in candidemia versus bacteremia: a systematic review. Crit Care. 2019;23(1):190. https:\/\/doi.org\/10.1186\/s13054-019-2481-y.","journal-title":"Crit Care"},{"issue":"7","key":"852_CR45","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00134-022-06733-x","volume":"48","author":"F Bloos","year":"2022","unstructured":"Bloos F, Held J, Kluge S, Simon P, Kogelmann K, de Heer G, et al. (1 \u2192 3)-\u03b2-D-glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Med. 2022;48(7):865\u201375. https:\/\/doi.org\/10.1007\/s00134-022-06733-x.","journal-title":"Intensive Care Med"},{"issue":"6","key":"852_CR46","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00134-019-05599-w","volume":"45","author":"I Martin-Loeches","year":"2019","unstructured":"Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, Einav S, De Waele JJ, et al. ESICM\/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019;45(6):789\u2013805. https:\/\/doi.org\/10.1007\/s00134-019-05599-w. (Epub 2019 Mar 25 PMID: 30911804).","journal-title":"Intensive Care Med"},{"issue":"Suppl 1","key":"852_CR47","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1-38. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.002. (Epub 2018 Mar 12 PMID: 29544767).","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"852_CR48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","volume":"102","author":"F Tissot","year":"2017","unstructured":"Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433\u201344. https:\/\/doi.org\/10.3324\/haematol.2016.152900.","journal-title":"Haematologica"},{"issue":"2","key":"852_CR49","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/mmy\/myy052","volume":"57","author":"JD Jenks","year":"2019","unstructured":"Jenks JD, Mehta SR, Hoenigl M. Broad spectrum triazoles for invasive mould infections in adults: which drug and when? Med Mycol. 2019;57(2):S168-S178S.","journal-title":"Med Mycol"},{"issue":"Suppl 7","key":"852_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19\u201337. https:\/\/doi.org\/10.1111\/1469-0691.12039. (PMID: 23137135).","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"852_CR51","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/cid\/civ885","volume":"62","author":"PE Verweij","year":"2016","unstructured":"Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62(3):362\u20138.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"852_CR52","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1093\/jac\/dkac196","volume":"77","author":"L Kriegl","year":"2022","unstructured":"Kriegl L, Hatzl S, Zurl C, Reisinger AC, Schilcher G, Eller P, Gringschl Y, et al. Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2022;77(9):2500\u20135. https:\/\/doi.org\/10.1093\/jac\/dkac196.","journal-title":"J Antimicrob Chemother"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-024-00852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-024-00852-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-024-00852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T21:05:11Z","timestamp":1718831111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-024-00852-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s11046-024-00852-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3267976\/v1","asserted-by":"object"}]},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,5]]},"assertion":[{"value":"16 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MH received research funding and\/or speaker and consultancy fees from Gilead, Astellas, MSD, Euroimmune, IMMY, Pulmocide, Mundipharma, Scynexis, F2G, and Pfizer. DAE received fees for lectures and consultancy from Tillots and Gilead. DW reports consultant and lecture fees from 3\u00a0M, Advants, AMEOS, Eumedica, EUSA, Gilead, InfectoPharm, Kite, Lilly, MSD, Novartis, Pfizer, and Shionogi. DWy has received speaker and consultancy fees from Gilead and Shionogi. AC received fees for lectures or consultancy by Gilead, MSD, Mundipharma, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"A statement of consent was included at the start of the survey and consent was implied by completion and submission of the survey. Consent was therefore sought from the participating HCPs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Participants were informed that the aim was to publish aggregated data from the survey in a peer-reviewed journal. A statement of consent was included at the start of the survey and consent was implied by completion and submission of the survey.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"41"}}